Composite ctDNA Response Scoring for NSCLC Treatment Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for calculating molecular response from circulating tumor DNA (ctDNA) levels are often inaccurate and lack effective integration of baseline ctDNA levels and changes over time, hindering precise prediction of patient response to treatment and cancer progression.
Innovation Solution
A method utilizing machine learning algorithms to analyze baseline ctDNA levels and longitudinal changes in ctDNA, incorporating features like mutant allele fractions and central tendency measures, to predict time to death or cancer progression events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing methods calculate molecular response using only ctDNA change, then the calculation is simple, but the prediction accuracy is low
Solution Approach 1:
The patent combines baseline ctDNA level and longitudinal ctDNA change into a unified molecular response score calculation. By merging these two previously separate measurements into a single composite metric, the method achieves more accurate treatment response prediction while maintaining a relatively streamlined calculation process.
Solution Approach 2:
The patent introduces a new parameter (baseline ctDNA level) to the existing molecular response calculation framework. This parameter change transforms the calculation from considering only ctDNA change to considering both baseline level and change, thereby improving prediction accuracy without excessive complexity.
2Reliability
If baseline ctDNA level is incorporated into molecular response calculation, then prediction of patient prognosis is improved, but the calculation becomes more complex
Solution Approach 1:
The patent merges baseline ctDNA level with longitudinal ctDNA change into a single molecular response score. This combination approach improves prognosis prediction reliability by utilizing multiple prognostic indicators simultaneously while presenting the result as a unified, easy-to-interpret score.
Solution Approach 2:
The patent performs preliminary measurement and recording of baseline ctDNA level before treatment begins. This preliminary action allows the baseline value to be readily available for subsequent molecular response calculations, improving prognosis prediction without adding complexity to the ongoing monitoring process.
3Measurement precision
If multiple ctDNA measurements are integrated, then molecular response score accuracy is enhanced, but data processing complexity increases
Solution Approach 1:
The patent integrates multiple ctDNA measurements (baseline level and longitudinal change) into a single molecular response score through a unified calculation formula. This merging approach enhances score accuracy by incorporating multiple data points while maintaining straightforward data processing through a single integrated equation.
Data Source
AI summary
Provided herein are methods of determining a molecular response score for use in predictive models. The molecular response score may be used to monitor and guide administration of treatment to a subject.